Following the excitement and controversy around the US approval of Biogen’s Alzheimer’s drug Aduhelm, Bayer has announced progress on its next-generation therapies for another currently incurable brain disorder, Parkinson’s disease.
Bayer acquired cell therapy specialist BlueRock Therapeutics in 2019 and gene therapy company Asklepios BioPharmaceutical (AskBio) the following year, and...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
